Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: Primum non nocere

Practical Diabetes International

Volumn 24, Issue 8, 2007, Pages 422-425

  Ryder, R E J ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; FRACTURE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LEG AMPUTATION; LEG REVASCULARIZATION; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; STROKE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 54849407225     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1168     Document Type: Article

References (21)

1. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007; 356: 2457-2471.
2. Psaty BM, Furberg CD. The Record on Rosiglitazone and the Risk of Myocardial Infarction. N Engl J Med 2007; 357: 67-69.
3. Reaven G. Insulin Resistance, Hypertension, and Coronary Heart Disease. J Clin Hypertens 2003; 5: 269-274.
4. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
5. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
6. Erdmann E, Dormandy JA, Charbonnel B, et al, on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49: 1772-1780.
7. Wilcox R, Bousser MG, Betteridge DJ, et al, on behalf of the PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865-873.
8. Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetics. Pharmacoepidemiol Drug Saf (DOI: 10.1002/pds.1470). http://www3.interscience.wiley.com/cgi-bin/abstract/ 114300391/ABSTRACT [accessed 23 August 2007].
9. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
10. Singh S, Loke YK, Furberg CD. Thiazolidinediones and Heart Failure - A teleo-analysis. Diabetes Care 2007; 30: 2148-2153.
11. BBC news, Friday 27 July 2007. Diabetes drugs 'pose heart risk'. http://news.bbc.co.uk/1/hi/health/6914434.stm [accessed 7 August 2007].
12. Diabetes UK website, Friday 27 July 2007. Can glitazones increase heart failure risk? http://www.diabetes. org.uk/About_us/News_Landing_Page/ Can-glitazones-increase-heart-failure-risk/ [accessed 7 August 2007].
13. Erdmann, E, Charbonnel B, Wilcox RG, et al. Pioglitazone Use and Heart Failure in Patients with Type 2 Diabetes and Preexisting Cardiovascular Disease: Data from the PROactive Study (PROactive 08). Diabetes Care published online ahead of print 31 July 2007. http://care.diabetesjournals.org/cgi/content/abstract/dc07-0717v1 [accessed 23 August 2007].
14. Drummond R, Fisher M. Fractures, heart failure and fears of myocardial ischaemia: has the RECORD stuck for rosiglitazone and the thiazolidinediones? Pract Diabetes Int 2007; 24: 324-327.
15. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
16. Schwartz AV, Sellmeyer DE. Thiazolidinedione Therapy Gets Complicated: Is bone loss the price of improved insulin resistance? Diabetes Care 2007; 30: 1670-1671.
17. Takeda. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus (Letter to Health Care Providers), March 2007. Available from http://www.fda.gov/medwatch/safety/2007/ Actosmar0807.pdf [accessed 6 August 2007].
18. Yki-Järvinen H. Drug therapy: thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
19. Anonymous (Lancet editorial). Rosiglitazone: seeking a balanced perspective. Lancet 2007; 369: 1834.
20. Tanne JH. FDA committees say keep rosiglitazone available but increase warnings. BMJ 2007; 335: 223.
21. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and Risk of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus - A Meta-analysis of Randomized Trials. JAMA 2007; 298(10): 1180-1188.